PMID- 24919820
OWN - NLM
STAT- MEDLINE
DCOM- 20150924
LR  - 20221207
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Print)
IS  - 1462-8902 (Linking)
VI  - 17
IP  - 3
DP  - 2015 Mar
TI  - Ipragliflozin in combination with metformin for the treatment of Japanese 
      patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, 
      placebo-controlled study.
PG  - 304-8
LID - 10.1111/dom.12331 [doi]
AB  - This multicenter, double-blind, placebo-controlled study examined the efficacy 
      and safety of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in 
      combination with metformin in Japanese patients with type 2 diabetes mellitus 
      (T2DM). Patients were randomized in a 2 : 1 ratio to 50 mg ipragliflozin 
      (n = 112) or placebo (n = 56) once daily for 24 weeks, followed by a 28-week 
      open-label extension in which all patients received 50 or 100 mg ipragliflozin, 
      while continuing metformin. The primary outcome was the change in glycated 
      haemoglobin (HbA1c) from baseline to week 24. HbA1c decreased significantly in 
      the ipragliflozin group (-0.87%; adjusted mean difference from placebo: -1.30%; 
      p < 0.001). The overall incidence of treatment-emergent adverse events was 
      similar in both groups, although pollakiuria and constipation were more common in 
      the ipragliflozin group; thus, ipragliflozin significantly improved glycaemic 
      control and reduced body weight without major safety issues in Japanese patients 
      with T2DM.
CI  - (c) 2014 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & 
      Sons Ltd.
FAU - Kashiwagi, A
AU  - Kashiwagi A
AD  - Department of Medicine, Shiga University of Medical Science, Shiga, Japan.
FAU - Kazuta, K
AU  - Kazuta K
FAU - Goto, K
AU  - Goto K
FAU - Yoshida, S
AU  - Yoshida S
FAU - Ueyama, E
AU  - Ueyama E
FAU - Utsuno, A
AU  - Utsuno A
LA  - eng
PT  - Letter
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140731
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Blood Glucose)
RN  - 0 (Glucosides)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Placebos)
RN  - 0 (Thiophenes)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 3N2N8OOR7X (ipragliflozin)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Aged
MH  - Asian People
MH  - Blood Glucose/drug effects
MH  - Body Weight/drug effects
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Double-Blind Method
MH  - Drug Therapy, Combination/methods
MH  - Female
MH  - Glucosides/*therapeutic use
MH  - Glycated Hemoglobin/drug effects
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Male
MH  - Metformin/*therapeutic use
MH  - Middle Aged
MH  - Placebos
MH  - Thiophenes/*therapeutic use
PMC - PMC4342773
OTO - NOTNLM
OT  - Japanese
OT  - SGLT2
OT  - ipragliflozin
OT  - metformin
OT  - randomized controlled trial
OT  - type 2 diabetes
EDAT- 2014/06/13 06:00
MHDA- 2015/09/25 06:00
PMCR- 2015/02/27
CRDT- 2014/06/13 06:00
PHST- 2014/02/10 00:00 [received]
PHST- 2014/05/13 00:00 [revised]
PHST- 2014/06/09 00:00 [accepted]
PHST- 2014/06/13 06:00 [entrez]
PHST- 2014/06/13 06:00 [pubmed]
PHST- 2015/09/25 06:00 [medline]
PHST- 2015/02/27 00:00 [pmc-release]
AID - 10.1111/dom.12331 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2015 Mar;17(3):304-8. doi: 10.1111/dom.12331. Epub 2014 Jul 
      31.